 | Up a level |
von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, PL; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, HF; for, the Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of internal medicine, 167(16), pp. 1782-90. Chicago, Ill.: American Medical Association 10.1001/archinte.167.16.1782
Ananworanich, J; Gayet-Ageron, A; Le Braz, M; Prasithsirikul, W; Chetchotisakd, P; Kiertiburanakul, S; Munsakul, W; Raksakulkarn, P; Tansuphasawasdikul, S; Sirivichayakul, S; Cavassini, M; Karrer, U; Genné, D; Nüesch, R; Vernazza, P; Bernasconi, E; Leduc, D; Satchell, C; Yerly, S; Perrin, L; ... (2006). CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, 368(9534), pp. 459-65. London: Elsevier 10.1016/S0140-6736(06)69153-8
Müller, V; Ledergerber, B; Perrin, L; Klimkait, T; Furrer, H; Telenti, A; Bernasconi, E; Vernazza, P; Günthard, HF; Bonhoeffer, S; Swiss, HIV Cohort Study (2006). Stable virulence levels in the HIV epidemic of Switzerland over two decades. AIDS, 20(6), pp. 889-94. Hagerstown, Md.: Lippincott Williams & Wilkins
Schüpbach, J; Günthard, H; Joos, B; Fischer, M; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B; Swiss, HIV Cohort Study (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Journal of acquired immune deficiency syndromes JAIDS, 40(3), pp. 250-6. Philadelphia, Pa.: Lippincott Williams & Wilkins
Kaufmann, GR; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M; Swiss, HIV Cohort Study (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical infectious diseases, 41(3), pp. 361-72. Cary, N.C.: The University of Chicago Press 10.1086/431484
